Hologic, Inc. revised earnings guidance for the Fiscal year 2024. For the year, the Company expects revenues of $4,000 million to $4,050 million compared to previous guidance of $3,990 million to $4,065 million and GAAP EPS of $3.45 to $3.55 compared to previous guidance of $3.52 to $3.67.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.86 USD | -1.28% | -1.33% | +3.50% |
May. 22 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
May. 22 | FDA classifies recall of Hologic's implants for soft tissue as 'most serious' | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.50% | 17.46B | |
+10.44% | 226B | |
+13.26% | 198B | |
+18.05% | 142B | |
+28.99% | 111B | |
+2.09% | 65.26B | |
+14.68% | 54.36B | |
+6.68% | 50.94B | |
+8.33% | 44.8B | |
+3.19% | 36.8B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024